Cases

Taxotere Permanent Hair Loss Lawsuits

If you’ve received a cancer diagnosis and have gone through chemotherapy or other treatments, you likely often have many questions going through your mind: will I be able to handle any other drugs I am prescribed after treatment, what’s next in my treatment schedule, and ultimately, will I stay cancer-free? While you may have some temporary hair loss from chemotherapy, worrying about permanent hair loss should not have to be a concern. However, some women, breast cancer survivors in particular, have reported a link between permanent hair loss and the chemotherapy drug Taxotere®.

Motley Rice attorneys are reviewing cases involving women who took the chemotherapy drug Taxotere® and have suffered from permanent hair loss or permanent significant alopecia following six months or more of significant lack of hair regrowth.

Taxotere Side Effects

Taxotere is given through injection and is associated with side effects that are common for chemotherapy drugs, including mouth sores, nausea, excessive fatigue, muscle or bone pain, and low platelet count.

An increasing number of women have reported permanent hair loss to the FDA as a result of being treated with Taxotere, claiming that they were not warned of a potential side effect of permanent hair loss. While it is a common side effect for cancer patients to lose body hair during treatment, permanent significant alopecia (hair loss) was not added to the Taxotere label by the FDA until December 2015.

Contact a Taxotere Lawyer

If you or someone you love has suffered from permanent hair loss and took the chemotherapy drug Taxotere, you may have a claim. Please contact medical drug attorney Kimberly Barone Baden by email or call 1.800.768.4026.

Taxotere Background

Taxotere is an anti-cancer chemotherapy drug that also goes by the generic name Docetaxel. Taxotere is classified as a “plant alkaloid” and was approved by the FDA in 2006 for treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer. The chemotherapy drug is also being studied to treat small cell lung cancer, ovarian cancer, bladder cancer and pancreatic cancer, soft tissue sarcoma and melanoma.

In 2010, Sanofi-Aventis removed language from its label that “hair generally grows back.”

In December 2015, Sanofi-Aventis added in the Adverse Reactions section of the Taxotere label that:  “Cases of permanent hair loss have been reported.”